CPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Catalyst Pharmaceuticals Inc (CPRX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has demonstrated strong revenue growth and positive market strategies, the recent financial performance shows a decline in net income, EPS, and gross margin. Additionally, technical indicators suggest a neutral to slightly bullish trend, but there are no clear trading signals or significant catalysts to justify an immediate buy. The options data indicates bearish sentiment with a high put-call volume ratio, and stock trend analysis predicts potential short-term declines. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in CPRX at this time.
The MACD is slightly positive and expanding, indicating a weak bullish trend. The RSI is neutral at 65.934. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 24.256, R1: 24.873, S1: 23.639, R2: 25.254, S2: 23.258. Overall, the technical indicators suggest a neutral to slightly bullish trend.
The company reported record revenues of $589 million for 2025, a 19.8% increase YoY. FIRDAPSE and AGAMREE revenues grew significantly, and 2026 revenue guidance is strong, projected between $615 million and $645 million. The company is enhancing market strategies for key products.
Stock trend analysis predicts potential short-term declines (-0.85% next day, -2.75% next week, -5.82% next month). Options data indicates bearish sentiment with a high put-call volume ratio of 12.94.
In Q4 2025, revenue increased by 7.61% YoY to $152.6 million. However, net income dropped by 5.79% YoY to $52.7 million, EPS decreased by 6.82% YoY to 0.41, and gross margin declined by 1.84% YoY to 76.71%.
No recent analyst rating or price target changes available.
